Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus FLURBIPROFEN SODIUM.
CHILDREN'S MOTRIN vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID